PMID: 8597462Dec 29, 1995Paper

DHEAS as an effective vaccine adjuvant in elderly humans. Proof-of-principle studies

Annals of the New York Academy of Sciences
B AraneoT Evans

Abstract

We have demonstrated that in aged mice, the titer of serum antibody induced against tetanus toxoid correlates with resistance to local paralysis caused by injection of tetanus toxin. Only mice immunized shortly after oral dosing with DHEAS demonstrated high serum antibody titers and complete protection from paralysis. These results became the basis for initiating proof-of-principle studies in human volunteers above age 65 using a licensed influenza vaccine and tetanus toxoid in two independent studies. The use of an oral delivery form of DHEAS before influenza vaccination was associated with a demonstrable increase in the number of individuals with a fourfold increase in HAI titers following vaccination. The overall mean increase in HAI titers was highest in the DHEAS-treated group. The use of DHEAS in the immunization of elderly subjects against tetanus toxoid, while unable to enhance the responses, was not a detriment to antibody response. We conclude that further studies will justify the use of DHEAS as an adjuvant for antigens that represent primary responses in the elderly.

References

Jan 1, 1979·Journal of Gerontology·A Członkowska, J Korlak
Jan 1, 1991·International Review of Cytology·R A Miller
Jan 1, 1989·Advances in Immunology·M L Thoman, W O Weigle
Jan 1, 1989·Journal of Gerontology·R A Miller
Apr 1, 1988·Annals of Internal Medicine·W W WilliamsA R Hinman
Sep 1, 1984·The Journal of Clinical Endocrinology and Metabolism·N OrentreichJ H Vogelman
Jul 1, 1980·Proceedings of the Society for Experimental Biology and Medicine·A J AmmannR Austrian
Mar 23, 1995·The New England Journal of Medicine·P J GergenG Virella
Mar 23, 1995·The New England Journal of Medicine·J P Sanford
Nov 1, 1993·The Journal of Emergency Medicine·J P Richardson, A L Knight
Sep 1, 1957·The Journal of Clinical Endocrinology and Metabolism·C J MIGEONT H SHEPARD
Jan 1, 1959·The Journal of Clinical Investigation·D B LOURIAD E ROGERS
Mar 1, 1991·Archives of Gerontology and Geriatrics·J J O'Leary, H M Hallgren

❮ Previous
Next ❯

Citations

Nov 15, 1997·Journal of the American Geriatrics Society·R A Miller
May 25, 1999·Periodontology 2000·W P McArthur
Apr 10, 1999·Journal of Clinical Pharmacology·P D KrobothR F Frye
May 18, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jonathan D KurtisLuz P Acosta
Aug 12, 2000·Stress : the International Journal on the Biology of Stress·D M DiamondG M Rose
May 20, 2005·Endocrine Reviews·Jean M Kaufman, Alex Vermeulen
Sep 1, 1997·The Journal of Clinical Endocrinology and Metabolism·H D DanenbergG Friedman
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·T B Nippoldt
May 8, 2001·Archives of Biochemistry and Biophysics·J L FitzpatrickR A Prough
Feb 11, 1998·Clinical Microbiology Reviews·L A Pirofski, A Casadevall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.